<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004261</url>
  </required_header>
  <id_info>
    <org_study_id>CAN-OCI-T98-0048</org_study_id>
    <secondary_id>CDR0000067516</secondary_id>
    <secondary_id>NCI-T98-0048</secondary_id>
    <nct_id>NCT00004261</nct_id>
  </id_info>
  <brief_title>EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma</brief_title>
  <official_title>A Phase I Trial of the Hypoxia Detection Agent EF5 (NSC 684681) in Patients With Cervix and Breast and Prostate Carcinomas, and High Grade Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: EF5 may detect the presence of oxygen in tumor cells and help plan effective
      cancer treatment.

      PURPOSE: Phase I trial to study the effectiveness of EF5 in detecting the presence of oxygen
      in tumor cells of patients who are undergoing surgery or biopsy for breast, prostate, or
      cervical cancer or high grade soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the optimal dose of etanidazole derivative EF5 that is safely
      tolerated and provides optimal binding in resected tumor specimens or tumor biopsies in
      patients with breast, head and neck, prostate, or cervical carcinoma or high grade soft
      tissue sarcomas. II. Define the toxic effects of EF5 in this patient population.

      OUTLINE: This is a dose-escalation study. Patients receive etanidazole derivative EF5 IV over
      1-2 hours. Approximately 24-48 hours after EF5 treatment, patients undergo surgical resection
      or biopsy of tumor. Cohorts of 6 patients receive escalating doses of EF5 until the maximum
      tolerated dose (MTD) or optimal dose is determined. The MTD is defined as the dose preceding
      that at which 2 of 6 patients experience dose-limiting toxicity. The optimal dose is defined
      as the dose level at or preceding the MTD and resulting in optimal tumor-to-normal-tissue
      binding. Patients are followed at 28 days.

      PROJECTED ACCRUAL: A total of 18-36 patients will be accrued for this study within 12-18
      months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of patient accrual
  </why_stopped>
  <start_date>December 1999</start_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EF5</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorescent antibody technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven breast, head and neck, prostate, or cervical
        carcinoma or high grade (defined as grades 2 or 3) soft tissue sarcoma Sarcoma tumors must
        be confined to truncal or extremity locations Must have a clinical condition and
        physiologic status which demonstrates that the appropriate or standard initial therapy for
        the tumor is surgical biopsy or resection Tumors no greater than 15 cm in any diameter
        Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance
        status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count
        greater than 2,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin less than
        2.0 mg/dL Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 50
        mL/min Cardiovascular: No significant cardiac disease that would preclude the safe use of
        general anesthesia Pulmonary: No significant pulmonary disease that would preclude the safe
        use of general anesthesia Other: Not pregnant or nursing Negative pregnancy test Fertile
        patients must use effective contraception during and for 1 month after study No grade 3 or
        4 peripheral neuropathy

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified
        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease
        Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Fyles, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2000</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage 0 cervical cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage IVB cervical cancer</keyword>
  <keyword>stage IA cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I nasopharyngeal cancer</keyword>
  <keyword>stage II nasopharyngeal cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>stage 0 paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage 0 nasopharyngeal cancer</keyword>
  <keyword>stage 0 oropharyngeal cancer</keyword>
  <keyword>stage 0 laryngeal cancer</keyword>
  <keyword>stage 0 hypopharyngeal cancer</keyword>
  <keyword>stage I salivary gland cancer</keyword>
  <keyword>stage II salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>stage 0 lip and oral cavity cancer</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage I lip and oral cavity cancer</keyword>
  <keyword>stage II lip and oral cavity cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>stage I hypopharyngeal cancer</keyword>
  <keyword>stage II hypopharyngeal cancer</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>stage I laryngeal cancer</keyword>
  <keyword>stage II laryngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>stage I paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage II paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage I oropharyngeal cancer</keyword>
  <keyword>stage II oropharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <keyword>stage II adult soft tissue sarcoma</keyword>
  <keyword>stage I adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

